Safely Tested
Patented
Made in the USA
Safely Tested
Patented
Made in the USA
Safely Tested
Patented
Made in the USA
Safely Tested
Patented
Made in the USA
Safely Tested
Patented
Made in the USA
Safely Tested
Patented
Made in the USA
Non-Carcinogenic
Nicotine-free
Non-Mutagenic
Tobacco-free
Non-Carcinogenic
Nicotine-free
Non-Mutagenic
Tobacco-free
Non-Carcinogenic
Nicotine-free
Non-Mutagenic
Tobacco-free
Non-Carcinogenic
Nicotine-free
Non-Mutagenic
Tobacco-free
Non-Carcinogenic
Nicotine-free
Non-Mutagenic
Tobacco-free
Non-Carcinogenic
Nicotine-free
Non-Mutagenic
Tobacco-free
Our Ingredients
The History of Nixodine™
Testing Nixodine™
nAChr Activation Study
α4β2
Nicotinic α4β2 receptors have high affinity for nicotine and account for >90% of nicotine binding to brain tissue.
nAChr Activation Study
α3β4
Nicotinic α3β4 receptors are involved in nicotine reward and physical withdrawal.
nAChr Activation Study
α6/3/β2β3
Nicotinic α6/3/β2β3 receptors are involved in nicotine-stimulated dopamine release and may play a role in nicotine dependence.